RESUMEN
The AP-2 transcription factors are required for normal growth and morphogenesis during mammalian development. Previous in vitro studies have also indicated that the AP-2 family of proteins may be involved in the etiology of human breast cancer. The AP-2 genes are expressed in many human breast cancer cell lines, and critical AP-2-binding sites are present in both the ERBB-2 (HER2/neu) and estrogen receptor promoters. We have now characterized immunological reagents that enable specific AP-2 family members, including AP-2alpha and AP-2gamma, to be detected in human breast cancer epithelium. Data obtained with these reagents demonstrate that whereas AP-2alpha and AP-2gamma are both present in benign breast epithelia, there is a significant up-regulation of AP-2gamma expression in breast cancer specimens (P = 0.01). There was also a significant correlation between the presence of the AP-2alpha protein and estrogen receptor expression (P = 0.018) and between specimens containing both AP-2alpha/AP-2gamma proteins and ERBB-2 expression (P = 0.003). Furthermore, we detected an association (P = 0.04) between the expression of AP-2gamma and the presence of an additional signal transduction molecule implicated in breast cancer, the insulin-like growth factor I receptor. Analysis of the proximal promoter of the insulin-like growth factor I receptor revealed a novel AP-2-binding site. Thus, AP-2 proteins may directly regulate the transcription of this growth factor receptor. Taken together, these data strongly support a role for the AP-2 gene family in the control of cell growth and differentiation in breast cancer.
Asunto(s)
Neoplasias de la Mama/metabolismo , Proteínas de Unión al ADN/biosíntesis , Receptores de Factores de Crecimiento/fisiología , Transducción de Señal/fisiología , Factores de Transcripción/biosíntesis , Sitios de Unión , Mama/metabolismo , Epitelio/metabolismo , Femenino , Humanos , Inmunohistoquímica , Pronóstico , Regiones Promotoras Genéticas/fisiología , Receptor ErbB-2/biosíntesis , Receptor IGF Tipo 1/genética , Receptores de Estrógenos/biosíntesis , Receptores de Factores de Crecimiento/biosíntesis , Receptores de Factores de Crecimiento/genética , Receptores de Progesterona/biosíntesis , Factor de Transcripción AP-2 , Células Tumorales Cultivadas , Regulación hacia Arriba/fisiologíaRESUMEN
The macrophage colony-stimulating factor receptor (CSF-1R), the product of the c-fms proto-oncogene, regulates normal proliferation and differentiation of macrophages and trophoblasts. Recent research found abnormal expression of CSF-1R in human carcinomas of the breast, endometrium, and ovary. Furthermore, activation of CSF-1R by its ligand has been shown to regulate invasiveness and anchorage-independent growth in breast carcinoma cells. To study the significance of CSF-1R expression in breast cancer, we designed a case-controlled immunohistochemical study. We chose 80 patients from a database of 1200 early stage I or II breast cancer patients treated with conservative surgery and radiation therapy. Expression of CSF-1R in the tumors of 40 patients who experienced an ipsilateral breast tumor recurrence (IBTR) as a primary site of relapse were compared with 40 patients who had not experienced an IBTR. The index and control patients were matched by age, clinical stage, nodal status, and follow-up. Paraffin-embedded sections were immunostained with antibodies directed toward CSF-1R. For the CSF-1R antibody, a total of 28 index cases (70%) demonstrated strong staining, whereas only 16 control cases (40%) demonstrated high immunoreactivity (P = 0.007). The CSF-1R antibody showed a positive correlation for local relapse, but no correlation was found between CSF-1R expression and distant metastasis. In summary, our findings provide evidence for the poor prognostic role of CSF-1R in IBTR.
Asunto(s)
Neoplasias de la Mama/ultraestructura , Recurrencia Local de Neoplasia/ultraestructura , Receptores del Factor Estimulante de Colonias/biosíntesis , Adulto , Anciano , Neoplasias de la Mama/patología , Estudios de Cohortes , Femenino , Humanos , Persona de Mediana Edad , Recurrencia Local de Neoplasia/patología , Estadificación de Neoplasias , Pronóstico , Proto-Oncogenes Mas , Receptores de Estrógenos/análisis , Receptores de Progesterona/análisis , Coloración y EtiquetadoRESUMEN
The macrophage colony stimulating factor receptor (CSF-1R), the product of the c-fms proto-oncogene, plays an important role in regulating the normal proliferation and differentiation of macrophages and trophoblasts. However, the abnormal expression of CSF-1R transcripts and protein by human breast carcinomas has been shown to correlate with advanced stage and poor prognosis. Ligand activated CSF-1R dimers transphosphorylate several tyrosines in their cytoplasmic domains which provide recognition sites for various effector proteins in multiple signal transduction pathways. In cells transformed by the c-fms oncogene, one of the major CSF-1R phosphotyrosines, pTyr723 is important for phenotypic expression of anchorage-independent growth and metastasis. In order to investigate the relationship between receptor activation/phosphorylation and cellular phenotypes in vitro and in vivo, we prepared a CSF-1R phosphorylation-state specific antibody raised against a specific phosphopeptide of CSF-1R, which included phosphorylated tyrosine 723. On immunoblots of lysates from cells expressing CSF-1R, this antibody recognizes phosphorylated CSF-IR in CSF-1 stimulated cells but not in unstimulated cells. As an immunohistochemical reagent, this antibody stained 52% of invasive human breast tumors (72% of CSF-1R positive cases) in a sample of 114 cases and 38% of carcinoma in situ. This data represents the first direct evidence of in vivo phosphorylation of CSF-1R in human breast carcinomas.
Asunto(s)
Anticuerpos/química , Neoplasias de la Mama/metabolismo , Fosfopéptidos/inmunología , Fosfotirosina/inmunología , Receptor de Factor Estimulante de Colonias de Macrófagos/inmunología , Secuencia de Aminoácidos , Animales , Especificidad de Anticuerpos , Neoplasias de la Mama/diagnóstico , Carcinoma in Situ/metabolismo , Células Cultivadas , Reacciones Cruzadas , Epítopos , Fibroblastos/metabolismo , Genes fms/fisiología , Humanos , Inmunohistoquímica , Macrófagos/metabolismo , Ratones , Ratones Endogámicos BALB C , Fosforilación , Proto-Oncogenes Mas , Receptor de Factor Estimulante de Colonias de Macrófagos/metabolismo , Células Tumorales CultivadasRESUMEN
We review our collective experience over the past 4 years using a portable instrument that measures the International Normalized Ratio (INR) and the prothrombin time (PT). The device can be used readily in ambulatory clinic settings and by patients in their homes. The major advantage of the monitor is that the INR/PT can be measured quickly; if a change in the dose of warfarin is necessary, instructions can be discussed directly with the patient at the time of the visit. Compared with clinical laboratory determinations, monitor INRs are quite accurate, with approximately 85% of measurements within 0.9 INR units of the corresponding laboratory value. If necessary, monitor INRs can be adjusted to approximate a specific clinical laboratory's INRs with a regression formula derived from analysis of duplicate INRs using the monitor and the laboratory. Although the Food and Drug Administration has not yet approved use of the monitor by patients at home, use of a portable measuring device in the home by home health agencies may be valuable in selected cases.